Business Wire

BACARDI

Share
From USA to France and From UK to Mexico, Bacardi Diverts Global Production to Increase Hand Sanitizer Supply for Local Communities

Family-owned Bacardi has expanded its commitment across countries and brands to help produce more than 267,000 gallons (1.1 million liters) of hand sanitizers, as worldwide demand continues to exceed supply in efforts to reduce the risk of COVID-19. This week, eight Bacardi-owned manufacturing sites across the United States, Mexico, France, England, Italy and Scotland are joining the efforts, following last week’s announcement that Bacardi in Puerto Rico would supply alcohol to make hand sanitizers. Across the sites, Bacardi is diverting its global production power, resources and processes to supply the much-needed alcohol essential for the increased production of hand sanitizers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005615/en/

Bacardi is also playing a part in donating these products to local organizations and emergency responders, as well as its employees and contractors. In addition, the company is providing alcohol at cost to select partner companies looking to ramp up their production of hand sanitizers for commercial sale. These temporary, emergency actions at all locations will not disrupt the supply of brands in the Bacardi portfolio.

“Over our 158-year history, we have risen to many challenges and we are doing the same again in response to COVID-19,” said Jean-Marc Lambert, SVP Global Operations for Bacardi. “All our brands and partners involved in this initiative will help people most in need benefit from the supply of these hand sanitizers. Our goal is to make a very real difference in the fight against COVID-19.”

The current list of sites providing support either immediately or in the coming week are:

  • BACARDÍ rum in Puerto Rico – partnered with Puerto Rico based manufacturer Olein Refinery to provide raw materials that will enable the production of more than 1.7M units of 10-ounce (300 ml) hand sanitizers. Donated product to local USPS, firefighters, police and non-profit Somos Unidos (United Way);
  • Bacardi Bottling Corporation in Jacksonville, FL, USA – is planning to help produce approximately 23,000 gallons (87,000 liters) to make 120,000 units of 25-ounce (750 ml) bottles hand sanitizer for donation to local hospitals, firefighters and police. In addition, the team will supply 7,600 gallons (29,000 liters) to nearby manufacturers.
  • BACARDÍ rum in Tultitlán, Mexico – supplying more than 5,200 gallons (20,000 liters) of alcohol to nearby manufacturer, Grupo Sterk, to help increase production of hand sanitizer by approximately 6,300 gallons (24,000 liters), of which 2,100 gallons (8,000 liters) will be donated by Bacardi to local communities in Tultitlán, Arandas and Atotonilco;
  • GREY GOOSE® vodka in Cognac, France – will supply 7,600 gallons (29,000 liters) of alcohol per day to French companies to increase supply of hand sanitizers by 9,500 gallons (36,000 liters) for local pharmacies, hospitals and the emergency services;
  • BOMBAY SAPPHIRE® gin in Hampshire, England – is helping to produce a small quantity of hand sanitizers that will be donated to local doctors, chemists and care homes;
  • MARTINI in Pessione, Italy – is supplying alcohol for the production of 1,000 7-ounce (200ml) hand sanitizers for the local community, Red Cross and local emergency services;
  • DEWAR’S® Blended Scotch Whisky in Aberfeldy, Scotland – is helping to produce a small quantity of hand sanitizers for the Scottish Ambulance Association among other local community groups;
  • ANGEL’S ENVY® Kentucky Straight Bourbon in Louisville, KY, USA – is supplying nearly 1,000 gallons (3,800 liters) of alcohol to create approximately 16,000 8-ounce (250 ml) bottles of free hand sanitizers for first responders and healthcare professionals.

All hand sanitizers produced in collaboration with Bacardi contain more than the minimum alcohol content recommended by the World Health Organization for containing the spread of the virus.

About Bacardi

The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye